Suzuken Co (9987) AI Stock Analysis

• Market Cap: $327.42B
• Dividend Yield: 1.68%
• Average Volume (3M): 163.97K
• Price to Earnings (P/E): 13.1
• Beta (1Y): 0.43
• Revenue Growth: 1.37%
• EPS Growth: -1.55%
• Country: JP
• Employees: 13,086
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 52.63
• Shares Outstanding: 72,167,206
• 10 Day Avg. Volume: 143,650
• 30 Day Avg. Volume: 163,966
• PEG Ratio: 0.40
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 0.16
• P/FCF Ratio: -4.48
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.11
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: 5.18
• 1Y Price Target: $6,677.49
• Price Target Upside: 15.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ¥6,387.00 ▲(10.56% Upside)

Suzuken Co's overall stock score reflects a strong balance sheet and moderate valuation, but is tempered by significant revenue decline and cash flow challenges. Technical indicators suggest a stable market position, but the lack of earnings call data and corporate events limits further insights.

Suzuken Co Business Overview & Revenue Model

Company Description

Suzuken Co., Ltd. (9987) is a leading Japanese pharmaceutical wholesaler and distributor, primarily engaged in the healthcare sector. The company operates in the distribution of pharmaceuticals, medical devices, and other healthcare-related products. In addition to its core distribution services, Suzuken offers logistics, information technology solutions, and consulting services to healthcare providers, contributing to the efficient management of medical supply chains.

How the Company Makes Money

Suzuken Co. generates revenue primarily through its distribution services, where it acts as an intermediary between pharmaceutical manufacturers and healthcare providers, including hospitals and pharmacies. The company's revenue model is based on the markup it applies to the products it distributes, which includes a wide range of prescription medications, over-the-counter drugs, and medical supplies. Key revenue streams also include logistics services and IT solutions provided to clients, enhancing supply chain efficiency and data management in healthcare settings. Additionally, Suzuken has established partnerships with various pharmaceutical companies, enabling it to secure a diverse product portfolio and maintain competitive pricing, further contributing to its earnings.

Suzuken Co Financial Statement Overview

Summary

Suzuken Co's financial performance is marked by a strong balance sheet with low leverage and effective equity utilization. However, the sharp decline in revenue growth and cash flow issues are significant concerns that need addressing to ensure liquidity and operational sustainability.

Income Statement

Suzuken Co's income statement shows a stable gross profit margin of around 8% over the years, indicating consistent cost management. The net profit margin has improved slightly, reaching 1.44% in the latest year, reflecting better profitability. However, the revenue growth rate has turned negative at -45.2%, which is a significant concern. EBIT and EBITDA margins have shown slight improvements, suggesting operational efficiencies.

Balance Sheet

The balance sheet of Suzuken Co is strong, with a very low debt-to-equity ratio of 0.0044, indicating minimal leverage and financial risk. The return on equity has improved to 8.47%, showing effective use of equity to generate profits. The equity ratio is healthy, suggesting a stable financial structure with a good proportion of assets financed by equity.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in the latest period, indicating liquidity issues. The free cash flow to net income ratio is positive, suggesting that despite negative cash flows, the company is generating sufficient net income. However, the operating cash flow to net income ratio is negative, highlighting potential cash flow management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.41T	2.40T	2.39T	2.31T	2.23T	2.13T
Gross Profit	192.18B	192.23B	185.25B	179.69B	167.33B	157.84B
EBITDA	49.42B	62.38B	51.40B	39.48B	32.55B	22.92B
Net Income	33.32B	34.50B	29.02B	20.34B	14.39B	7.89B
Balance Sheet
Total Assets	1.15T	1.11T	1.23T	1.15T	1.14T	1.11T
Cash, Cash Equivalents and Short-Term Investments	142.20B	141.58B	242.11B	192.70B	201.46B	212.12B
Total Debt	23.85B	1.80B	1.80B	1.80B	2.12B	2.28B
Total Liabilities	744.12B	706.41B	812.26B	734.57B	723.66B	696.51B
Stockholders Equity	402.16B	407.29B	416.31B	411.21B	417.69B	417.05B
Cash Flow
Free Cash Flow	0.00	-83.73B	71.58B	19.53B	-4.77B	7.74B
Operating Cash Flow	0.00	-65.08B	87.22B	37.27B	9.52B	15.60B
Investing Cash Flow	0.00	20.38B	10.35B	-46.36B	1.44B	-14.59B
Financing Cash Flow	0.00	-35.48B	-31.72B	-26.22B	-11.60B	-7.39B

Suzuken Co Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5777.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Neutral. The current price of 5777 is below the 20-day moving average (MA) of 5863.00, below the 50-day MA of 5872.46, and above the 200-day MA of 5340.01, indicating a neutral trend. The MACD of 0.65 indicates Positive momentum. The RSI at 45.70 is Neutral, neither overbought nor oversold. The STOCH value of 44.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9987.

Suzuken Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2784	74 Outperform	$415.53B	14.44	4.94%	3.03%	5.11%	-20.51%
9987	69 Neutral	$327.42B	13.10	7.09%	1.68%	1.37%	-1.55%
7459	68 Neutral	¥478.28B	13.22	6.39%	2.52%	3.88%	-10.72%
3151	67 Neutral	¥56.38B	6.25	―	4.61%	2.23%	72.07%
3549	67 Neutral	¥409.14B	22.70	―	0.39%	15.81%	27.05%
8129	60 Neutral	¥307.48B	14.62	―	1.76%	2.31%	19.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Suzuken Co Corporate Events

Suzuken Co. Records Extraordinary Gain from Securities Sale

Suzuken Co., Ltd. has announced an extraordinary gain from the sale of investment securities, amounting to ¥15,567 million, as part of a strategic review and reduction of its cross-shareholdings. This gain will be recorded in the financial results for the fiscal year ending March 31, 2026, but it will not affect the company’s earnings forecast as the impact has already been accounted for.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen6387.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.

Suzuken Co. Reports September 2025 Share Repurchase Results

Suzuken Co., Ltd. announced the results of its share repurchase for September 2025, acquiring 358,400 common shares for approximately ¥2.15 billion through market purchases on the Tokyo Stock Exchange. This repurchase is part of a larger plan, announced in May 2025, to buy back up to 5.2 million shares by March 2026, aiming to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen6387.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.

Suzuken Co. Announces August Share Repurchase Results

Suzuken Co., Ltd. announced the results of its share repurchase program for August 2025, acquiring 491,400 common shares for approximately ¥2.87 billion through market purchases on the Tokyo Stock Exchange. This repurchase is part of a larger plan to buy back up to 5.2 million shares, representing 7.21% of total shares outstanding, by March 2026, which may impact the company’s stock value and shareholder equity.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen6387.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.

Suzuken Co. Reports Q1 2025 Financial Results with Mixed Performance

Suzuken Co., Ltd. reported its consolidated financial results for the three months ending June 30, 2025, showing a slight increase in net sales by 1.8% year-on-year. Despite the rise in operating and ordinary profit, the profit attributable to owners of the parent decreased by 23.8%. The company maintains a stable financial position with total assets of ¥1,146,413 million and a capital adequacy ratio of 35.1%. The forecast for the fiscal year ending March 31, 2026, anticipates a modest increase in net sales but a decline in profits, reflecting challenges in maintaining profitability.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen5730.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.

Suzuken Co. Reports Progress on Share Repurchase Program

Suzuken Co., Ltd. announced the results of its share repurchase program for July 2025, acquiring 584,000 common shares for approximately ¥3.15 billion through market purchases on the Tokyo Stock Exchange. This is part of a larger initiative to repurchase up to 5.2 million shares by March 2026, reflecting the company’s strategy to enhance shareholder value and optimize its capital structure.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen5800.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.